Hit enter to search or ESC to close
COVID-19 vaccine maker AstraZeneca announced Thursday that its antibody drug is more than 80% effective at reducing risk of severe disease or death.
The company said new data from the AZD7442 COVID-19 Provent prevention and Tackle outpatient treatment Phase III trials showed “robust efficacy” from a one-time intramuscular dose of the long-acting antibody (LAAB) combination.
FAUCI: COVID-19 HOSPITALIZATIONS RISING AMONG VACCINATED
Analysis of the ongoing Provent trial with a six-month follow-up found that one 300- mg intramuscular dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%.
“The AZD7442 PROVENT trial is the first Phase III trial prospectively designed to evaluate a monoclonal antibody for pre-exposure prophylaxis of symptomatic COVID-19, with targeted inclusion of high-risk and immunocompromised participants. More than 75% of PROVENT participants at baseline had co-morbidities that put them at high risk for severe COVID-19 if they were to become infected, including people who are immunocompromised and may have a reduced immune response to vaccination,” AstraZeneca wrote.
There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442 at either the initial or six-month analyses.
In this Wednesday, March 10, 2021, file photo, a health worker administers a dose of the AstraZeneca vaccine against COVID-19 to a patient inside the convention center known as “La Nuvola,” The Cloud, in Rome.
(AP Photo/Andrew Medichini, file)
Comparatively, in the placebo arm, there were two additional cases of severe COVID-19 at the six-month assessment and five in total. There were also two COVID-related deaths.
An exploratory analysis of a separate treatment trial – the Tackle outpatient treatment trial – found that one 600-mg intramuscular dose of AZD7442 reduced the risk of patients with mild-to-moderate COVID-19 developing severe COVID-19 or death by 88%, compared with placebo in patients who had been symptomatic for three days or less at the time of treatment.
SEVERAL CALIFORNIA CHILDREN SICK AFTER CLINIC ADMINISTERS WRONG COVID-19 VACCINE DOSES
AstraZeneca noted that 90% of the participants enrolled in Tackle were from populations at high risk of progression to severe COVID-19 if they became infected, including those with comorbidities.
“In both PROVENT and TACKLE, AZD7442 was generally well tolerated,” it said. “No new safety issues were identified in the six-month analysis of PROVENT.”
“AZD7442 is the only long-acting antibody with Phase III data to demonstrate benefit in both pre-exposure prophylaxis and treatment of COVID-19 with one dose. These new data add to the growing body of evidence supporting AZD7442’s potential to make a significant difference in the prevention and treatment of COVID-19,” Mene Pangalos, executive vice president of biopharmaceuticals research and development at AstraZeneca, said in a statement. “We are progressing regulatory filings around the world and look forward to providing an important new option against SARS-CoV-2 as quickly as possible.”
The full results from both trials will be submitted for publication in a peer-reviewed medical journal and presented at a forthcoming medical meeting.
CLICK HERE TO GET THE FOX NEWS APP
In October, AstraZeneca announced that it had submitted a request to the Food and Drug Administration for Emergency Use Authorization for AZD7442 – or Evusheld – “for prophylaxis of COVID-19.”
If regulators greenlight authorization, the company has agreed to supply the U.S. government with 700,000 doses of AZD7442.
About the author
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.